Schizophrenia News

The FDA has accepted a new drug application for aripiprazole, a 2-month, ready-to-use, long-acting injectable for the treatment of schizophrenia in adults and maintenance monotherapy treatment of bipolar I disorder in adults.

Researchers at Aston University in England have received funding to explore new methods of recording electrical signals emitted from brain cells, which could lead to potential treatment for conditions like epilepsy and schizophrenia.

Karuna Therapeutics Inc. announced positive results from its phase 3 EMERGENT-2 trial evaluating the efficacy, safety and tolerability of its investigational therapy for adults with schizophrenia.

McLean Hospital in Belmont, Massachusetts, has been named the top hospital in the United States for psychiatric care by the U.S. News & World Report for 2022 to 2023.

Avant Institute received a grant from Davos Alzheimer’s Collaborative to perform cognitive screening at pharmacies in rural and underserved communities nationwide, according to a press release.

Despite advances in treatment, patients with schizophrenia have faced obstacles in obtaining an education, with the largest gap occurring in high-income countries, according to a study published in Lancet Psychiatry.

NEW ORLEANS – The American Psychiatric Association DSM steering committee gathered at the APA annual meeting to review proposed changes to the manual, committee chair Paul S. Appelbaum, MD, said.

NEW ORLEANS — Most investigators concluded that telemedicine is satisfactory for patients with schizophrenia being treated with long-acting injectable psychotics, according to survey results presented at the American Psychiatric Association meeting.

NEW ORLEANS – For the first time in 3 years, the American Psychiatric Association will host its annual meeting in person, May 21 to 25 in New Orleans, with social determinants of mental health as the conference theme.

The FDA has issued a Complete Response Letter for the New Drug Application for risperidone extended-release injectable for subcutaneous use, a schizophrenia treatment, Teva Pharmaceuticals and MedinCell announced in a statement.